CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASEConfidential Separation Agreement and General Release • February 13th, 2017 • Nivalis Therapeutics, Inc. • Pharmaceutical preparations • Colorado
This Confidential Separation Agreement and General Release (this “Agreement”) is entered into by and between Nivalis Therapeutics, Inc. (“EMPLOYER”) and Jon Congleton (“EMPLOYEE”). For purposes of this Agreement, EMPLOYER includes TriNet Group, Inc. (“TriNet”) as well as any company related to EMPLOYER, in the past or present; the past and present officers, directors, employees, shareholders, attorneys, agents, insurers and representatives of EMPLOYER; any present or past employee benefit plan sponsored by EMPLOYER and/or the officers, directors, trustees, administrators, employees, attorneys, agents, insurers and representatives of such plan; and any person who acted on behalf of EMPLOYER or on instruction from EMPLOYER.
AMENDMENT to the EMPLOYMENT AGREEMENT between Nivalis Therapeutics, Inc. andEmployment Agreement • February 13th, 2017 • Nivalis Therapeutics, Inc. • Pharmaceutical preparations
WHEREAS, Nivalis Therapeutics, Inc. (the “Company”) and the Employee entered into an employment agreement (the “Agreement”) effective as of November 1, 2012, as amended;
Nivalis Therapeutics, Inc.Nivalis Therapeutics, Inc. • February 13th, 2017 • Pharmaceutical preparations • Colorado
In recognition of your continued service with Nivalis Therapeutics, Inc. (the “Company”), and subject to the other terms and conditions of this letter agreement (this “Agreement”), we are pleased to offer you a retention bonus in the amount of $100,000.00, less applicable withholdings and deductions required by law (the “Retention Bonus”) and an option grant to purchase 200,000 shares of Common Stock of the Company which option shall vest in full upon the termination of your employment by the Company other than for Cause or a Corporate Transaction (as defined in the stock option agreement to be entered into by you and the Company) and be subject to the terms and conditions of such stock option agreement and the Company’s 2015 Equity Incentive Plan (the “Stock Option”).
AMENDMENT to the EMPLOYMENT AGREEMENT between Nivalis Therapeutics, Inc. and Jon Congleton (“Employee”)Employment Agreement • February 13th, 2017 • Nivalis Therapeutics, Inc. • Pharmaceutical preparations
WHEREAS, Nivalis Therapeutics, Inc. (the “Company”) and the Employee entered into an employment agreement (the “Agreement”) effective as of January 1, 2015, as amended;
AMENDMENT to the EMPLOYMENT AGREEMENT between Nivalis Therapeutics, Inc. and David M. Rodman, M.D. (“Employee”)Employment Agreement • February 13th, 2017 • Nivalis Therapeutics, Inc. • Pharmaceutical preparations
WHEREAS, Nivalis Therapeutics, Inc. (the “Company”) and the Employee entered into an employment agreement (the “Agreement”) effective as of April 18, 2016;
Nivalis Therapeutics, Inc.Nivalis Therapeutics, Inc. • February 13th, 2017 • Pharmaceutical preparations • Colorado
In recognition of your continued service with Nivalis Therapeutics, Inc. (the “Company”), and subject to the other terms and conditions of this letter agreement (this “Agreement”), we are pleased to offer you a retention bonus in the amount of $100,000.00, less applicable withholdings and deductions required by law (the “Retention Bonus”) and an option grant to purchase 200,000 shares of Common Stock of the Company which option shall vest in full upon the termination of your employment by the Company other than for Cause or a Corporate Transaction (as defined in the stock option agreement to be entered into by you and the Company) and be subject to the terms and conditions of such stock option agreement and the Company’s 2015 Equity Incentive Plan (the “Stock Option”).
AMENDMENT to the EMPLOYMENT AGREEMENT between Nivalis Therapeutics, Inc. andEmployment Agreement • February 13th, 2017 • Nivalis Therapeutics, Inc. • Pharmaceutical preparations
WHEREAS, Nivalis Therapeutics, Inc. (the “Company”) and the Employee entered into an employment agreement (the “Agreement”) effective as of January 21, 2015;
